Biosimilar drugs: Economic issues and Italian market perspectives;Biosimilari Aspetti economici e prospettive per il mercato italiano

PharmacoEconomics - Italian Research Articles

Volumn 12, Issue 1, 2010, Pages 17-31

  Jommi, C ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG COST; DRUG MARKETING; ECONOMIC ASPECT; IMMUNOGENICITY; MEDICAL RESEARCH; PROSPECTIVE PRICING; REVIEW; SYNTHESIS;

EID: 77953862251     PISSN: 15909158     EISSN: 20356137     Source Type: Journal    
DOI: 10.1007/BF03320527     Document Type: Review

References (44)

1. Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: evolution or revolution for generics companies? London: Pricewaterhouse Coopers LLP 2006 (www.pwc.com/uk/strategy)
2. Avalere Health. Estimating US savings from follow-on biologics. Biosimilars: how much entry and price competition will result. OHE Conference. London, June 2, 2009
3. Horikawa H, Tsubouchi M, Kawakami K. Industry views of biosimilar development in Japan. Health Policy 2009; 91: 189-194
4. Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008; 7: 733-737
5. Grabowski H, Wang R. The quantity and the quality of worldwide new drug introductions 1982-2003. Health Aff 2006; 25: 452-460
6. Jommi C. La valutazione economica dei farmaci biotecnologici. Conferenza Nazionale Farmaci Biotecnologici in Oncologia. Torino, 26-28 novembre 2009
7. Osservatorio Farmaci. Report 23. Report annuale per il. Milano: Cergas Bocconi, 2008
8. Genazzani A, Biggio G, Caputi AP, et al. Biosimilar drugs: concerns and opportunities. Biodrugs 2007; 21: 351-356
9. Di Masi J, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 2007; 28: 469-479
10. Perayre Badia M, Leiva E, Jódar R. Biotecnológicos y bio-similares: El proceso es el producto. Atención Farmacéutica 2007; 9: 358-364
11. Tucker J, Yakatan S, Yakatan S. Biogenerics 2007: how far have we come? J Commer Biotechnol 2008; 14: 56-64
12. Goldsmith D, Kuhlmann M, Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol 2007; 11: 191-195
13. Blackstone AE, Fuhr Jr JP. Why biosimilars will have a smaller competitive edge than generics. Journal of Health Care Finance 2008; 35: 84-95
14. Tsiftsoglou AS. Biosimilars: the impact of their heterogeneity on regulatory approval. Nat Rev Drug Discov 2007; 6
15. Schellekens H. Follow-on biologics: challenges of the "next Generation". Nephrol Dial Transplant 2005; 20 Suppl. 4: iv31-6
16. Grabowski HG. The US Data Exclusivity debate: balancing innovation, incentives and cost savings. Biosimilars: how much entry and price competition will result. OHE Conference. London, June 2, 2009
17. Grabowski HG, Cockburn I, Long G. The market for follow-on biologics: how will it evolve? Health Aff 2006; 25: 1291-1301
18. Grabowski HG. Patents and new product development in the pharmaceutical and biotechnology industries. The Georgetown Public Policy Review 2003; 8: 7-24
19. Kuhlmann MK, Goldsmith D, Covic A. Biosimilars: current status. Int J Pharm Med 2007; 21: 199-206
20. Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006; 11: 341-346
21. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20 Suppl. 6: vi3-9
22. Roger SD, Goldsmith D. Biosimilars: it's not simple as cost alone. J Clin Pharm Ther 2008; 33: 459-464
23. Sharma B. Immunogenicity of therapeutic proteins. Part 1: impact of product handling. Biotechnol Adv 2007; 25: 310-317 (Pubitemid 46498672)
24. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21 Suppl. 5: v9-12
25. EMEA. Committee for Medicinal Product for Human Use. Guideline on similar biological medicinal product, 2005 (ultimo accesso: 25 giugno 2009)
26. Kotlikoff LJ. Biosimilars, data exclusivity and the incentives for innovation: response to Grabowski. Boston University, March 17, 2009
27. Grabowski HG, Di Masi J. Biosimilars, data exclusivity, and the incentives for innovation: a critique to Kotlikoff's white paper. Duke University Department of Economics Working paper. No.2009-02, February 2009
28. Donnarumma E. Approfondimento su: farmaci biotecnologici e biosimilari. BIF 2008; 15
29. Duerden M. Prescribing advice needed for new biosimilar biological drugs. Prescriber 2007; 19 novembre 2007, pagine 1-2
30. (Parere del) Consiglio di Stato, Sezione Prima, 20 giugno 2007: Regione Molise. Quesito sull'applicazione dell'equivalenza terapeutica tra farmaci, nel caso di acquisto di medicinali da parte di pubblici soggetti tramite gara
31. Tribunale Amministrativo Regionale per l'Emilia Romagna, Sezione Seconda, Sentenza N. 00001/2009 del 2 gennaio 2009
32. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Managerial and Decision Economics 2007; 28: 439-451
33. Chauhan D, Towse A, Mestre-Ferrandiz J. The markets for biosimilars: evolution and policy options. OHE Briefing 45, October 2008. London: OHE, 2008
34. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Marketing Strategy 1997; 6: 75-90
35. Engel & Novitt. Potential savings that might be realized. A report to PCMA. January 2, 2007 (www.pcmanet.org )
36. Miller S, Houts J. Potential savings of biogenerics in the United States. Express Scripts 2007 (www.expressscripts.com )
37. Ahlstrom A, King R, Brown R, et al. Modeling federal cost savings from follow-on biologics. Avalere 2007 (www.avalerehealth.net )
38. Grabowski HG. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 2008; 7: 479-488
39. Congressional Budget Office, June 25, 2008. Biologics Price Competition and Innovation Act of 2007. Cost estimate for the bill as ordered reported by the Senate Committee on Health, Education, Labor, and Pensions on June 27, 2007 (doc9496/s1695.pdf)
40. Patel S. A perspective on the biogeneric opportunity. The S.A.M. Newsletter 2004; 3.3: 4-13
41. Shapiro RJ. The potential American market for generic biological treatments and the associated cost savings. February 2008
42. Howrey LLP, Cap Analysis & phRMA. The inflated projections of potential cost savings from follow-on biologics: an analysis of the Express Scripts and Engel & Novitt reports. Howrey Cap Analysis. May 2007
43. Johnson JA. FDA regulation of follow-on biologics. CRS Report for Congress. Washington, DC: Congressional Research Service, 2009
44. Gottlieb S. Policy, clinical and regulatory considerations. Am J Health Syst Pharm 2008; 65 Suppl. 6: S2-8